SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178913-22-001896
Filing Date
2022-05-12
Accepted
2022-05-12 06:20:45
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8k.htm   iXBRL 8-K 34330
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 143664
  Complete submission text file 0001178913-22-001896.txt   373342

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20220512.xsd EX-101.SCH 4701
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20220512_def.xml EX-101.DEF 18329
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20220512_lab.xml EX-101.LAB 28549
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20220512_pre.xml EX-101.PRE 20565
8 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 6623
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 22915580
SIC: 2834 Pharmaceutical Preparations